For more information or to collaborate, please contact:
Professor Michael Seckl (Research)
+44 (0)20 3311 1421
Tina Barker (Clinical)
Why it is important
Lung cancer accounts for more deaths than any other cancer in both men and women.
What we do
Most cancer deaths are due to the development of drug-resistant and metastatic disease. For this reason, a lot of our research efforts focus on elucidating the underlying mechanisms that govern these two processes.
How it can benefit patients
Our work combines basic, translational and clinical research to identify novel therapeutic targets for lung cancer in collaboration with both academic and industrial partners.
Summary of current research
- Cell signalling events underlying drug resistance in cancer
- Identification of novel mediators of cancer cell metastasis and resistance to treatments
- Metabolic changes associated with lung cancer progression
- Cross-talk between cancer cells and their microenvironment
- RNA interference and drug screening
- Development of new therapies to our targets
- Clinical trials to test our new therapies